Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
8.150
+0.190 (+2.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 21, 2023
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
August 21, 2023
Via
Benzinga
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
August 19, 2023
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a...
Via
Talk Markets
7 Analysts Have This to Say About Arcutis Biotherapeutics
August 10, 2023
Via
Benzinga
8 Analysts Have This to Say About Arcutis Biotherapeutics
July 18, 2023
Via
Benzinga
Analyst Ratings for Arcutis Biotherapeutics
June 28, 2023
Via
Benzinga
Arcutis Appoints Interim Chief Financial Officer (CFO)
August 18, 2023
Former and First Arcutis CFO, John Smither, Appointed Interim
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
August 10, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations for Arcutis Biotherapeutics's Future
June 12, 2023
Via
Benzinga
The Latest Analyst Ratings for Arcutis Biotherapeutics
May 17, 2023
Via
Benzinga
Arcutis to Report Second Quarter Financial Results
July 24, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
July 17, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
June 30, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Arcutis Biotherapeutics: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
Where Arcutis Biotherapeutics Stands With Analysts
March 29, 2023
Via
Benzinga
Why Shares of Arcutis Biotherapeutics Jumped This Week
June 09, 2023
The stock got a push when a British medical journal posted trials information on the company's lead product.
Via
The Motley Fool
Arcutis to Present at Upcoming Investor Conference
June 06, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
7 Short-Interest Stocks to Target for Explosive Gains
May 18, 2023
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 10, 2023
Via
Benzinga
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
May 02, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Global Payments, MGM Resorts And 3 Stocks To Watch Heading Into Monday
May 01, 2023
With US stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
April 28, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Report First Quarter Financial Results
April 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
April 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
April 05, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
March 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
March 09, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.